CHARLOTTE, N.C.–(BUSINESS WIRE)–#2015cehrt–Eye Care Leaders will present their comprehensive portfolio of HITRUST and 2015 certified solutions at booth #1942 at the ASCRS•ASOA Annual Symposium.
Author: Business Wire
Glaukos Files Patent Infringement Lawsuit Against Ivantis, Inc.
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that it has filed a patent infringement lawsuit against Ivantis, Inc. in the U.S. District Court for the Central District of California, Southern Division. The lawsuit alleges that Ivantis’ Hydrus Microstent device infringes Glauko
Global Diabetic Eye Disease Devices Market – Latest Developments by Technavio
LONDON–(BUSINESS WIRE)–#MedicalDevices–Market research firm Technavio has announced the release of their latest report on the global diabetic eye disease devices market for 2018-2022.
Global Cataract Surgical Devices Market 2018-2023 – IOLs are the Most Popular Product Type – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Cataract Surgical Devices Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2018-2023” report has been added to ResearchAndMarkets.com’s offering. According to the report, the global cataract su…
Omeros Corporation Announces Upcoming Presentations of New Data on OMIDRIA® at the American Society of Cataract and Refractive Surgery Meeting
SEATTLE–(BUSINESS WIRE)–Omeros Corporation (NASDAQ: OMER) today announced that the results of four studies directed to the benefits of OMIDRIA across a range of clinical situations in cataract surgery will be presented at the upcoming American Society of Cataract and Refractive Surgery (ASCRS) Congress in Washington, D.C., April 13-17, 2018. The four presentations are scheduled as follows: Saturday, April 14: 1:41 PM – 1:46 PMWalter E. Washington Convention Center – Room 143AMiosis Prevention
Compulink Showcases Innovative Mobile Patient Engagement Technology to Increase Revenue at AAOE 2018
THOUSAND OAKS, Calif.–(BUSINESS WIRE)–Compulink showcases innovative mobile patient engagement technology to increase revenue at AAOE 2018.
Dr. Nicole R. Fram of Advanced Vision Care to Present on modmed® Ophthalmology at the 2018 American Society of Cataract and Refractive Surgery (ASCRS) and American Society of Ophthalmic Administrators (ASOA) Annual Meeting
BOCA RATON, Fla.–(BUSINESS WIRE)–Specialty-specific health information technology leader Modernizing Medicine® today announced that Nicole R. Fram, M.D. of Advanced Vision Care will present on Sunday, April 15, during the EMR Industry Spotlight Theater at the 2018 ASCRS•ASOA Annual Meeting. Dr. Fram will educate attendees about her successes utilizing the modmed Ophthalmology suite and its intelligent electronic health record (EHR) system, EMA™, including best practices providers can employ u
Global $167 Billion Eyewear Market Report 2018 with Forecasts to 2023 by Product, Gender, and Distribution Channel – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Eyewear Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2018-2023” report has been added to ResearchAndMarkets.com’s offering. According to the report, the global eyewear market was valued at …
Global Vision Care Market 2018-2023 – Johnson & Johnson, Cooper, Valeant Pharma, Essilor, and Novartis are Dominating – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Vision Care Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2018-2023” report has been added to ResearchAndMarkets.com’s offering. According to the report, the global vision care market reache…
OMIDRIA® Added to Veterans Health Administration National Formulary
SEATTLE–(BUSINESS WIRE)–Omeros Corporation (Nasdaq: OMER) today announced that the Veterans Administration (VA) has added OMIDRIA® (phenylephrine and ketorolac intraocular solution 1% / 0.3%) to the VA National Formulary. The VA National Formulary is a listing of drugs and supplies that must be available at all VA facilities for the benefit of U.S. military veterans. Omeros’ commercial drug OMIDRIA is the first and only FDA-approved product to maintain pupil size by preventing intraoperative
Compulink Showcases Mobile Patient Engagement and AI-Driven EHR for Ophthalmology at ASCRS 2018
THOUSAND OAKS, Calif.–(BUSINESS WIRE)–Compulink showcases mobile patient engagement and AI-driven EHR for ophthalmology at ASCRS 2018.
Aerie Pharmaceuticals Announces Appointment of Scott Laranjo as Director, Marketing, Roclatan™
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced the appointment of Scott Laranjo as Director, Marketing, RoclatanTM, reporting to Deanne Melloy, Aerie’s Vice President of Marketing. Mr. Laranjo will direct future marketing activities associated w
SERI Lugano: FDA wählt ParaCel Riboflavin für die „Epi-on“-Hornhautquervernetzung zur Behandlung von Keratokonus
LUGANO, Schweiz–(BUSINESS WIRE)–Wie das Switzerland Eye Research Institute bekanntgab, wählte die FDA aus zahlreichen Alternativen die als ParaCel bekannte, bahnbrechende transepitheliale Riboflavinformulierung für die Behandlung von Patienten mit progressivem Keratokonus. ParaCel basiert auf den Resultaten der Forschungsarbeit von Dr. Pinelli, dem Gründer und CEO des Instituts. AVEDRO, Inc., Waltham, Mass. hatte 2011 alle Rechte am geistigen Eigentum erworben, die das Unternehmen zur Herstel
SERI Lugano: la riboflavina ParaCel scelta dalla FDA per il cross-linking epi-on per cheratocono
LUGANO, Svizzera–(BUSINESS WIRE)–Lo Switzerland Eye Research Institute ha annunciato che, secondo quanto riportato da un comunicato stampa, la rivoluzionaria formulazione a base di ribloflavina transepiteliale nota come ParaCel, frutto della ricerca dell’amministratore delegato e fondatore dell’istituto, il Dr. Roberto Pinelli, è stata scelta dalla FDA insieme a diverse altre per un protocollo di cross-linking del collagene corneale epi-on (senza asportazione dell’epitelio corneale) per i paz
SERI Lugano: ParaCel riboflavine geselecteerd door FDA voor epi-on crosslinking voor keratoconus
LUGANO, Zwitserland–(BUSINESS WIRE)–Het Switzerland Eye Research Institute heeft aangekondigd dat de doorbraakformulering voor transepitheliale riboflavine, bekend als ParaCel, en op basis van het onderzoek van haar CEO en oprichter Roberto Pinelli, MD, door de FDA uit vele inzendingen is geselecteerd voor een behandelprotocol voor epithelial-on corneale collageen crosslinking voor patiënten met progressieve keratoconus, volgens een persbericht. Alle intellectuele eigendomsrechten voor het pr
SERI Lugano : La riboflavine ParaCel est sélectionnée par la FDA pour être utilisée dans le cadre du crosslinking epi-on pour le kératocône
LUGANO, Suisse–(BUSINESS WIRE)–Le Switzerland Eye Research Institute a annoncé que la formulation de riboflavine transépithéliale novatrice, connue sous le nom de ParaCel et basée sur la recherche de son président-directeur général et fondateur Roberto Pinelli, MD, avait été sélectionnée parmi un grand nombre d’autres formulations par la FDA (Food and Drug Administration – Agence américaine de contrôle des produits alimentaires et médicamenteux) pour un protocole de crosslinking (CXL) (réticu
Global $58.44 Billion Ophthalmic Equipment Market Forecasts by Product, 2018-2023 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Ophthalmic Equipment Market by Product – Global Forecasts to 2023” report has been added to ResearchAndMarkets.com’s offering. The ophthalmic equipment market is expected to reach USD 58.44 billion by 2023 from USD 49.30 b…
Omeros Announces Amendment of Credit Facility
SEATTLE–(BUSINESS WIRE)–Omeros Corporation (Nasdaq: OMER) today announced that it has entered into an amendment to its existing credit facility with certain affiliates of CRG LP, a healthcare-focused investment firm. With respect to the twelve-month period beginning on January 1, 2018, the amendment deems Omeros to have met the financial covenants requiring the company to achieve a minimum net revenue or market capitalization amount. The net revenue and market capitalization covenants will co
SERI Lugano: ParaCel Riboflavin Selected by FDA for Epi-on Cross-Linking for Keratoconus
LUGANO, Switzerland–(BUSINESS WIRE)–ParaCel riboflavin invented by Dr. Roberto Pinelli, released to AVEDRO in 2011, has been chosen among others by the FDA for a new epi-on crosslinking.
LENSAR® Laser System Receives FDA Clearance to Perform Corneal Pockets and Flaps for Corneal Inlay Procedures
ORLANDO, Fla.–(BUSINESS WIRE)–LENSAR receives FDA clearance for LENSAR Laser System with Streamline IV to perform corneal pockets and flaps for corneal inlay procedures.